Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 07/26 02:01:14 pm
380.7 DKK   +2.75%
07/25 NOVO NORDISK A/ : - Share repurchase programme
07/23 NOVO NORDISK A/ : 66% of diabetes sufferers unaware
07/21 NOVO NORDISK A/ : The Digital Health Connection in Africa
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments.

The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity.

The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas.

The company was founded in 1923 by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen and is headquartered in Bagsværd, Denmark.

Number of employees : 40 638 persons.
Sales per Businesses
20142015Delta
DKK (in Million)%DKK (in Million)%
Diabetes & Obesity Care69,98078.8%85,59079.3% +22.31%
Biopharmaceuticals18,82621.2%22,33720.7% +18.65%
Sales per Regions
20142015Delta
DKK (in Million)%DKK (in Million)%
North America43,12348.6%56,85752.7% +31.85%
Europe20,15022.7%20,79819.3% +3.22%
International12,54014.1%14,96613.9% +19.35%
China8,0889.1%9,8719.1% +22.05%
Japan & Korea4,9055.5%5,4355% +10.81%
Managers
NameAgeSinceTitle
Lars Rebien Sørensen621982President & Chief Executive Officer
Göran Ando672005Chairman
Jesper Brandgaard, MBA531999Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen, PhD561991Chief Science Officer & Executive Vice President
Alan C. Moses, MD-2008Global Chief Medical Officer
Anne Marie Handrup Kverneland601981Director
Stig Strøbæk521992Director
Bruno Francois Jules Angelici, MBA692011Independent Non-Executive Director
Thomas Paul Koestler, PhD652011Independent Director
Elizabeth Anne Hewitt602012Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 2,012,564,000 1,796,581,297 89.3% 52,168,703 2.6% 70.5%
Share B 10 537,436,000 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk Fonden 163,814,000 8.14%
Capital Research & Management Co. (World Investors) 155,939,356 7.75%
The Vanguard Group, Inc. 37,016,130 1.84%
Norges Bank Investment Management 36,416,979 1.81%
Carmignac Gestion SA 27,869,686 1.38%
Northern Cross LLC 27,778,506 1.38%
BlackRock Investment Management (UK) Ltd. 22,698,811 1.13%
Alecta Pension Insurance Mutual 20,908,000 1.04%
Novo Nordisk A/S 19,927,645 0.99%
BlackRock Fund Advisors 16,277,706 0.81%
Holdings
NameEquities%Valuation
Novo Nordisk A/S (NOVO B) 19,927,6450.99%1,065,596,939 USD
Nnit A/S (NNIT) 6,375,00025.5%218,947,845 USD
Innate Pharma (IPH) 5,422,70810.1%62,894,303 USD
Pieris Pharmaceuticals Inc (PIRS) 2,051,8025.15%3,303,401 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
NOVO NORDISK A/S-6.23%110 385
JOHNSON & JOHNSON21.58%343 528
PFIZER INC.13.94%223 065
NOVARTIS AG-5.13%218 815
ROCHE HOLDING LTD.-9.62%217 668
MERCK & CO., INC.10.87%162 096
BRISTOL-MYERS SQUIBB C..9.84%126 133
SANOFI-2.66%108 444
GLAXOSMITHKLINE PLC20.68%105 867
ALLERGAN PLC-20.69%98 039
ELI LILLY AND CO-2.71%90 546
BAYER AG-20.02%84 345
ASTRAZENECA PLC-0.09%77 127
ABBOTT LABORATORIES-3.34%63 776
SHIRE PLC3.66%57 372
TEVA PHARMACEUTICAL IN..-17.45%49 801
TAKEDA PHARMACEUTICAL ..-23.90%34 553
ASTELLAS PHARMA INC-2.94%34 389
MYLAN NV-12.56%24 036
CHUGAI PHARMACEUTICAL ..-6.59%20 873
SHIONOGI & CO LTD0.15%18 293
Sector Pharmaceuticals - NEC
Novo Nordisk A/S : Connections
EUSA Pharma (Europe) Ltd.
RAND Health
The International Centre for Missing & Exploited Children
ImmusanT, Inc.
Essex Woodlands Health Ventures UK Ltd.
Steno Diabetes Center A/S
Archimedes Pharma UK Ltd.
Novo Nordisk Fonden
Essex Bidco Ltd.
Bio*One Capital Pte Ltd.
Novo Nordisk Region Japan & Korea A/S
Arisaph Pharmaceuticals, Inc.
Novo Nordisk Region Europe A/S
Novo A/S
Novo Nordisk Region International Operations A/S
University of Copenhagen
Novo Nordisk Gsc Holding A/S
New England Healthcare Institute
Bertelsmann Management SE
Symphogen A/S
Danmarks Nationalbank
SWMF Life Science Venture Fund LP
Carlsberg Breweries A/S
Melinta Therapeutics, Inc.
Novo Nordisk Region China A/S
Vatera Holdings LLC
Novo Nordisk Region North America Ii A/S
Pearl Therapeutics, Inc.
Novo Nordisk Holding Ltd.
Edgemont Pharmaceuticals LLC
Novo Nordisk China Pharmaceuticals Co. Ltd.
Novo Nordisk Pharmaceuticals A/S
Novo Nordisk Invest 2 A/S
Silverwood Property Ltd.
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsværd, Capital Region 2880

Phone : +45.44.44.88.88
Fax : +45.44.49.05.55
Web : www.novonordisk.com
© 2016 People , Fundamentals and Ownership